PriceTargets.com logo

Madrigal Pharmaceuticals - MDGL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $294.75
  • Forecasted Upside: 25.60%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$234.67 As of 03/24/2023 01:00 AM ET
▲ +2.71 (1.17%)

This chart shows the closing price for MDGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Madrigal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDGL

Analyst Price Target is $294.75
▲ +25.60% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $294.75, with a high forecast of $390.00 and a low forecast of $151.00. The average price target represents a 25.60% upside from the last price of $234.67.

This chart shows the closing price for MDGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in Madrigal Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2023Canaccord Genuity GroupBoost TargetBuy$296.00 ➝ $336.00Low
2/27/2023OppenheimerBoost TargetOutperform$250.00 ➝ $300.00Low
1/5/2023JMP SecuritiesBoost TargetMarket Outperform$312.00 ➝ $390.00Low
12/21/2022UBS GroupBoost TargetBuy$161.00 ➝ $337.00Low
12/20/2022SVB LeerinkBoost TargetOutperform$145.00 ➝ $315.00Low
12/20/2022Evercore ISIBoost Target$175.00 ➝ $325.00Low
12/20/2022CowenBoost Target$129.00 ➝ $309.00Low
12/20/2022OppenheimerBoost TargetOutperform$170.00 ➝ $250.00Low
12/19/2022JMP SecuritiesBoost TargetMarket Outperform$182.00 ➝ $312.00Low
12/19/2022Raymond JamesUpgradeUnderperform ➝ Market PerformLow
12/19/2022B. RileyBoost Target$75.00 ➝ $194.00Low
12/19/2022Piper SandlerBoost TargetOverweight$203.00 ➝ $280.00N/A
12/19/2022HC WainwrightBoost TargetBuy$170.00 ➝ $225.00N/A
12/19/2022The Goldman Sachs GroupBoost TargetBuy$178.00 ➝ $375.00N/A
12/1/2022HC WainwrightReiterated RatingBuyLow
7/8/2022B. RileyDowngradeBuy ➝ Neutral$131.00 ➝ $75.00N/A
5/12/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$133.00 ➝ $151.00Medium
5/10/2022OppenheimerLower Target$180.00 ➝ $170.00High
2/7/2022JMP SecuritiesReiterated RatingBuy$220.00High
11/17/2021JMP SecuritiesReiterated RatingBuy$219.00High
11/7/2021Evercore ISIInitiated CoverageBuy$199.00Low
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$151.00High
8/11/2021HC WainwrightLower TargetBuy$184.00 ➝ $170.00Low
8/6/2021BMO Capital MarketsUpgradeMarket Perform ➝ OutperformMedium
8/6/2021BMO Capital MarketsLower TargetMarket Perform$134.00 ➝ $111.00Medium
6/28/2021B. RileyReiterated RatingBuyLow
3/4/2021Chardan CapitalBoost TargetBuy$202.00 ➝ $203.00High
3/2/2021OppenheimerLower TargetOutperform$200.00 ➝ $190.00High
2/26/2021Chardan CapitalBoost TargetBuy$202.00 ➝ $203.00Medium
11/23/2020Evercore ISIReiterated RatingOutperform$180.00Low
11/8/2020OppenheimerReiterated RatingBuyMedium
11/6/2020Chardan CapitalReiterated RatingBuy$205.00Medium
11/6/2020The Goldman Sachs GroupBoost TargetNeutral$118.00 ➝ $126.00Low
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$119.00 ➝ $124.00Medium
11/6/2020HC WainwrightBoost TargetBuy$165.00 ➝ $184.00Medium
11/5/2020Piper SandlerLower TargetOverweight$208.00 ➝ $204.00High
8/6/2020OppenheimerReiterated RatingBuy$200.00Medium
8/6/2020Stifel NicolausReiterated RatingHold$114.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$208.00High
6/24/2020OppenheimerReiterated RatingBuy$200.00High
6/4/2020BMO Capital MarketsInitiated CoverageMarket Perform$135.00Medium
5/22/2020B. RileyBoost TargetBuy$134.00 ➝ $174.00High
5/8/2020HC WainwrightLower TargetBuy$215.00 ➝ $168.00Medium
5/7/2020Stifel NicolausReiterated RatingHold$116.00Medium
5/5/2020Chardan CapitalInitiated CoverageBuy$205.00High
4/15/2020B. RileyReiterated RatingBuy$134.00Low
4/14/2020Stifel NicolausReiterated RatingHoldLow
3/5/2020CitigroupLower Target$166.00 ➝ $155.00Low
2/27/2020CowenReiterated RatingBuyHigh
1/9/2020UBS GroupUpgradeNeutral ➝ Buy$125.00 ➝ $127.00High
1/2/2020SVB LeerinkReiterated RatingOutperformLow
12/2/2019CitigroupLower TargetBuy$173.00 ➝ $166.00High
11/12/2019CowenReiterated RatingBuyMedium
11/7/2019HC WainwrightLower TargetBuy$225.00 ➝ $215.00High
11/6/2019CowenReiterated RatingBuyHigh
9/17/2019CitigroupLower TargetBuy$186.00 ➝ $173.00Low
8/9/2019B. RileySet TargetBuy$134.00High
8/8/2019CowenReiterated RatingBuyLow
8/7/2019Stifel NicolausSet TargetHold$126.00Low
7/3/2019HC WainwrightReiterated RatingBuy$225.00Low
6/24/2019Stifel NicolausInitiated CoverageHold ➝ Hold$126.00Medium
6/10/2019B. RileyUpgradeNeutral ➝ Buy$126.00 ➝ $128.00Low
5/15/2019CitigroupLower TargetBuy$200.00 ➝ $186.00Medium
5/9/2019HC WainwrightReiterated RatingBuyLow
4/17/2019CowenReiterated RatingBuyHigh
3/28/2019UBS GroupBoost TargetNeutral ➝ Positive$143.00Medium
2/28/2019HC WainwrightReiterated RatingBuy ➝ Buy$313.00 ➝ $228.00Medium
2/22/2019SVB LeerinkInitiated CoverageOutperformLow
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$119.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/12/2018HC WainwrightReiterated RatingBuy$313.00Low
12/12/2018CitigroupLower TargetBuy$200.00Low
12/11/2018B. RileyInitiated CoverageNeutral ➝ Neutral$124.00 ➝ $124.00Low
12/4/2018OppenheimerSet TargetBuy$200.00High
11/19/2018OppenheimerLower TargetOutperform$300.00 ➝ $200.00High
11/19/2018Raymond JamesDowngradeMarket Perform ➝ UnderperformHigh
11/16/2018Evercore ISIUpgradeIn-Line ➝ Outperform$222.00 ➝ $250.00High
11/13/2018OppenheimerSet TargetBuy$300.00High
11/7/2018CowenReiterated RatingBuyHigh
9/18/2018OppenheimerSet TargetBuy$300.00High
9/4/2018CitigroupInitiated CoverageBuy ➝ Buy$340.00High
8/8/2018OppenheimerSet TargetBuy$300.00Low
8/6/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$314.00Medium
6/28/2018Raymond JamesInitiated CoverageMarket PerformMedium
6/27/2018Evercore ISIReiterated RatingIn-LineLow
6/7/2018Evercore ISILower TargetOutperform$300.00 ➝ $281.00Low
6/1/2018Roth CapitalBoost TargetBuy$210.00 ➝ $400.00Medium
6/1/2018HC WainwrightBoost TargetBuy ➝ Buy$178.00 ➝ $313.00Medium
5/31/2018CowenReiterated RatingBuyHigh
5/31/2018Evercore ISIBoost TargetOutperform$300.00Medium
5/31/2018OppenheimerUpgradeMarket Perform ➝ Outperform$300.00High
5/31/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
5/31/2018The Goldman Sachs GroupReiterated RatingBuy$191.00 ➝ $314.00High
5/31/2018JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $300.00High
5/24/2018HC WainwrightBoost TargetBuy$178.00Medium
5/10/2018CowenReiterated RatingBuyHigh
5/8/2018OppenheimerSet TargetHold$130.00Medium
4/16/2018OppenheimerInitiated CoverageHold$130.00Medium
4/13/2018CowenReiterated RatingBuyHigh
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 16 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Read More

Today's Range

Now: $234.67
Low: $224.76
High: $234.67

50 Day Range

MA: $274.28
Low: $231.06
High: $307.08

52 Week Range

Now: $234.67
Low: $57.15
High: $315.45

Volume

310,664 shs

Average Volume

528,893 shs

Market Capitalization

$4.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Madrigal Pharmaceuticals?

The following Wall Street research analysts have issued reports on Madrigal Pharmaceuticals in the last year: B. Riley, Canaccord Genuity Group Inc., Cowen Inc, Evercore ISI, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for MDGL.

What is the current price target for Madrigal Pharmaceuticals?

12 Wall Street analysts have set twelve-month price targets for Madrigal Pharmaceuticals in the last year. Their average twelve-month price target is $294.75, suggesting a possible upside of 25.6%. JMP Securities has the highest price target set, predicting MDGL will reach $390.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $151.00 for Madrigal Pharmaceuticals in the next year.
View the latest price targets for MDGL.

What is the current consensus analyst rating for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDGL will outperform the market and that investors should add to their positions of Madrigal Pharmaceuticals.
View the latest ratings for MDGL.

What other companies compete with Madrigal Pharmaceuticals?

Other companies that are similar to Madrigal Pharmaceuticals include Alkermes, Ionis Pharmaceuticals, Amicus Therapeutics, Ironwood Pharmaceuticals and Dynavax Technologies. Learn More about companies similar to Madrigal Pharmaceuticals.

How do I contact Madrigal Pharmaceuticals' investor relations team?

Madrigal Pharmaceuticals' physical mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company's listed phone number is (267) 824-2827 and its investor relations email address is [email protected] The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. Learn More about contacing Madrigal Pharmaceuticals investor relations.